Sanofi SEC Filings March 2026

Sanofi has filed three press releases in March 2026. Exhibit 99.1 announces that Sanofi's rilzabrutinib has received orphan drug designation in Japan for IgG4-related disease, based on positive Phase 2 study data. This designation underscores Sanofi's commitment to rare immune-mediated diseases. The press release also provides details on the drug's mechanism of action, ongoing Phase 3 trials, and its current regulatory status for other indications like immune thrombocytopenia. Exhibit 99.2 reports the filing of an amendment to Sanofi's French "Document d’Enregistrement Universel," which includes the Annual Financial Report and additions to the corporate governance report. This document is available on Sanofi's website and the French market regulator's website. Exhibit 99.3 details the proposal by Sanofi's Board of Directors to appoint Christel Heydemann as an independent director at the upcoming Annual General Meeting. The board also proposes the renewal of mandates for Christophe Babule and Jean-Paul Kress. Patrick Kron will step down from the Board after his term expires. Christel Heydemann's extensive experience in leading major international groups and her expertise in industrial and digital transformation are highlighted as valuable assets for Sanofi's future development. The proposed changes aim to further strengthen the diversity of expertise and backgrounds within the company's governance.